Novo Holdings A/S
Investment Details
Investor Type
Private Equity
Asset Class Focus
Private Equity, Venture Capital, Fixed Income (Debt and Bonds), Hedge Funds, Real Estate, Infrastructure, Commodities, Crypto, Distressed and Special Situations, ESG and Impact Investing, Collectibles & Art
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, Singapore, China, India, Brazil, France, Italy, Denmark, Switzerland, Spain, Mexico, South Korea, Netherlands, Russia, Sweden, Belgium, Norway, Finland
Industries Focus
- Financial Services
- Technology
- Healthcare
- Energy
- Consumer Goods
- Real Estate
- Infrastructure
- Materials
- Telecommunications
- Media
- Food and Beverage
- Life Sciences
- Healthcare Services
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Chemicals
- Consumer Health
- Agricultural Biotechnology
- Materials Science
- Environmental Services
Investment Size:
1,000,000 to 1,000,000,000 USD
Investor Details Founded: 1999
Novo Holdings A/S is a Danish private equity firm and holding company that manages the assets of the Novo Nordisk Foundation, one of the world's largest philanthropic enterprise foundations. Established in 1999, the company focuses on generating long-term returns to support the Foundation's scientific, humanitarian, and social initiatives. As the controlling shareholder of Novo Nordisk A/S and Novozymes A/S, Novo Holdings plays a pivotal role in the life sciences sector, investing in companies that develop, manufacture, or sell medicines, new treatment methods, or medical and health-related equipment.
In 2024, Novo Holdings reported record total income and investment returns of DKK 60 billion (€8.0 billion), with its investment portfolio delivering above-benchmark returns alongside strong growth at the Novo Group companies. The firm's diverse portfolio includes investments in life sciences, equities, bonds, real estate, infrastructure, and private equity. Notably, in February 2024, Novo Holdings agreed to acquire Catalent for $16.5 billion, aiming to boost supplies of the widely popular weight-loss drug Wegovy. This strategic acquisition underscores Novo Holdings' commitment to enhancing global healthcare through significant investments in the life sciences sector.
Requirements
- Investments in life sciences companies at all stages of development
- Active ownership and strategic guidance
- Focus on generating long-term returns
- Commitment to responsible investing and ESG principles
- Global investment approach with a focus on Europe, North America, and Asia
- Diversified portfolio including equities, bonds, real estate, infrastructure, and private equity assets
- Interest in companies developing treatments for various diseases, including cancer, obesity, and neurodegenerative disorders
- Active expansion into emerging markets, such as India
- Strong financial performance with a focus on achieving record total income and investment returns
- Commitment to making a positive impact on health, science, and society through investments
- Focus on life sciences investments
- Long-term investment horizon
- Support for scientific, humanitarian, and social initiatives
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Novo Nordisk A/S
- Novozymes A/S
- Catalent
- Xellia Pharmaceuticals
- Sonion
- Convatec
- Halodoc
- Evotec
- Clario
- F2G Limited
- NMD Pharma
- DADES
- Biosyntia
- Reapplix
- Acesion Pharma
- Orexo
Mentioned In
-
$9.95
-
$99.00
-
$39.95
-
$19.95
-
$24.95
-
$19.95
-
$24.95
-
$245.00
Claim this Investor
Are you an official representative of Novo Holdings A/S?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim